Sinphar Pharmaceutical CoTPE:1734 81 Days Inventory is 134.34 as of Dec. 2025, which is 10% below its 10-year median of 149.45. GuruFocus rates TPE:1734 with a GF Score™ of 81/100 and a GF Value™ of NT$33.16 (Fairly Valued). The stock has 2 warning signs investors should review. Among 637 Biotechnology companies, Sinphar Pharmaceutical Co ranks better than 61.07% on this metric.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Sinphar Pharmaceutical Co's Inventory Turnover for the
three
months ended in Dec. 2025 was 0.68.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Sinphar Pharmaceutical Co's Inventory-to-Revenue for the
three
months ended in Dec. 2025 was 0.83.
Sinphar Pharmaceutical Co (TPE:1734) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Sinphar Pharmaceutical Co's Inventory Turnover for the
three
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Sinphar Pharmaceutical Co's Inventory to Revenue for the
three
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Sinphar Pharmaceutical Co Days Inventory Related Terms
Sinphar Pharmaceutical Co Days Inventory Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1734 vs VRTX, REGN, ALNY: Days Inventory Comparison
For the Biotechnology subindustry, Sinphar Pharmaceutical Co's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinphar Pharmaceutical Co Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sinphar Pharmaceutical Co's Days Inventory distribution charts can be found below:
* The bar in red indicates where Sinphar Pharmaceutical Co's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinphar Pharmaceutical Co (TPE:1734) has a Days Inventory of 134.34 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Sinphar Pharmaceutical Co and its competitors. This is 10% below median its historical median of 149.45. Over the past decade, Sinphar Pharmaceutical Co's Days Inventory has ranged from 132.45 to 177.82. According to the industry distribution chart, Sinphar Pharmaceutical Co ranks #248 out of 637 companies in the Biotechnology industry, placing it in the top 38.9%.
Is Sinphar Pharmaceutical Co's Days Inventory too high?
Sinphar Pharmaceutical Co's current Days Inventory of 134.34 is 10% below median its 10-year median of 149.45. Over the past 10 years, this metric has ranged from a low of 132.45 to a high of 177.82. The Biotechnology industry median Days Inventory is 183.23. Sinphar Pharmaceutical Co's value of 134.34 is 26.7% below this industry median. Based on the distribution chart, Sinphar Pharmaceutical Co ranks #248 out of 637 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Sinphar Pharmaceutical Co has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sinphar Pharmaceutical Co's Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sinphar Pharmaceutical Co ranks #248 out of 637 companies for Days Inventory. This puts Sinphar Pharmaceutical Co in the upper half of its industry. The industry median Days Inventory is 183.23. Sinphar Pharmaceutical Co's value of 134.34 is 26.7% below this benchmark. Historically, Sinphar Pharmaceutical Co's own Days Inventory has ranged from 132.45 to 177.82 over the past decade. While the company's 10-year median is 149.45 vs. the industry median of 183.23, Sinphar Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.23, based on 637 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sinphar Pharmaceutical Co's current Days Inventory of 134.34 is 26.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Sinphar Pharmaceutical Co and its competitors. For the Biotechnology industry, the median Days Inventory is 183.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinphar Pharmaceutical Co's current Days Inventory is 134.34, which is 10% below median its own 10-year median of 149.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinphar Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Sinphar Pharmaceutical Co (TPE:1734) is currently considered Fairly Valued. The stock's GF Value™ is NT$33.16, compared to a current price of NT$33.10 — trading 0.2% below its estimated fair value. The current Days Inventory is 134.34, which is 10% below median its 10-year median of 149.45 and 26.7% below the Biotechnology industry median of 183.23. Sinphar Pharmaceutical Co's overall GF Score™ is 81/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Sinphar Pharmaceutical Co (TPE:1734), the current Days Inventory is 134.34 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinphar Pharmaceutical Co (TPE:1734) Overvalued in 2026?
Based on GuruFocus' analysis, Sinphar Pharmaceutical Co stock appears to be undervalued.
The current stock price of NT$33.10 is trading 0.2% below its estimated GF Value™ of NT$33.16.
GuruFocus considers Sinphar Pharmaceutical Co to be Fairly Valued.
Key valuation signals for TPE:1734:
Days Inventory: 134.34 (10% below median its 10-year median of 149.45)
GF Value™: NT$33.16 vs. price of NT$33.10 (0.2% below fair value)
Industry Position: 26.7% below the Biotechnology median (#248 of 637)
No single metric tells the full story. See the TPE:1734 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sinphar Pharmaceutical Co Ltd operates in the pharmaceutical segment. The company mainly engages in the production, processing, and trading of various Chinese medicines, medicinal cosmetics, and nutrients. The company's reportable segments are; Pharmaceuticals which derives key revenue, Healthy food, and others. Geographically, the company generates a majority of its revenue from Taiwan and the rest from China, Vietnam, Indonesia, America, and other regions.
81GF Score
Get the complete analysis for TPE:1734
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1734 has been successfully added to your 
